For the Inventor, By the Inventor

Enter assignee name

Princeton, NJ, United States of America

Bristol-Myers Squibb

USPTO Granted Patents = 39

% Expired Patents = 2.6

EPO Patents = 1

Forward Citations = 1,659

Loading Chart...

Loading Chart...

111 inventors (with patents filed for the assignee):

Chandra S Ramanathan (4 out of 33 patents)

William R Ewing (3 out of 85 patents)

Jeffrey A Robl (3 out of 81 patents)

4. John N Feder (3 out of 67 patents)

5. Paolo Lombardi (3 out of 31 patents)

6. Fabio Animati (3 out of 7 patents)

7. Andrew K Dilger (2 out of 17 patents)

8. Kumar Balashanmuga Pabbisetty (2 out of 15 patents)

9. Yeheng Zhu (2 out of 19 patents)

10. Stephen H Hoag (2 out of 22 patents)

11. James R Corte (2 out of 65 patents)

12. Kwan-Ho Chan (2 out of 36 patents)

13. Hajime Kamachi (2 out of 29 patents)

14. Clair L Strohl (2 out of 6 patents)

15. Jeffrey B Boggs (2 out of 3 patents)

Core Competencies:

Factor XIa Inhibitors

Therapeutic Peptides

Polynucleotides

Tumor Growth Modulation

Cannabinoid Receptor Modulators

Antiviral Agents

Anti-Malarial Agents

Pharmaceutical Formulations

Bone Cement Dispensing

MRI Contrast Agents

Taste-Masking Agents

39 patents: Sort by Forward Citations

1. 10287288 - Factor XIa macrocyclic inhibitors bearing alkyl or cycloalkyl P2' moieties (2019-05-14),

2. 10273236 - Macrocyclic factor XIa inhibitors bearing heterocyclic groups (2019-04-30),

3. 9273111 - Therapeutic TREM-1 peptides (2016-03-01),

4. 7153678 - Polynucleotides encoding the novel human phosphatase, RET31, and variants thereof (2006-12-26),

5. 7115375 - Methods of diagnosing renal tumors by determining the expression level of RNA encoding the HGPRBMY18 polypeptide (2006-10-03),

6. 7094572 - Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74 (2006-08-22),

7. 7041496 - DNA encoding rodent KCNQ2 potassium channel (2006-05-09),

8. 7037910 - Azabicyclic heterocycles as cannabinoid receptor modulators (2006-05-02),

9. 7037906 - Methods for modulating tumor growth and metastasis (2006-05-02),

10. 7037676 - Drosophila tumor necrosis factor class molecule polynucleotides and variants thereof (2006-05-02),

11. 6330845 - Wrench for an implant (2001-12-18),

12. 6214869 - Heterocyclic cis cyclopropane derivatives as melatonergic agents (2001-04-10),

13. 6187008 - Device for temporarily fixing bones (2001-02-13),

14. 6184231 - 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators (2001-02-06),

15. 6180651 - Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics (2001-01-30),

Company Overview

Bristol-Myers Squibb is a global biopharmaceutical company based in Princeton, NJ, specializing in the discovery, development, and delivery of innovative medicines. The organization focuses on areas such as oncology, immunology, cardiovascular disease, and fibrosis, leveraging advanced research and technology to address unmet medical needs. With a commitment to improving patient outcomes, Bristol-Myers Squibb collaborates with healthcare professionals and researchers worldwide to bring transformative therapies to market.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

39 Patents

#34 in Princeton, NJ

#359 in New Jersey

#8,830 in US

#17,465 in the World

Princeton, NJ, United States of America

Bristol-Myers Squibb

Forward Citations = 1,659

111 inventors:

Chandra S Ramanathan (4 out of 33 patents)

William R Ewing (3 out of 85 patents)

Jeffrey A Robl (3 out of 81 patents)

4. John N Feder (3 out of 67 patents)

5. Paolo Lombardi (3 out of 31 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Bristol-Myers Squibb. Retrieved from https://idiyas.com/company/bristol-myers-squibb

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…